Danaher Corporation Investors Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m. GMT. These events will be simultaneously webcast on www.danaher.com. ABOUT DANAHER Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life. Explore more at www.danaher.com. SOURCE Danaher Corporation
|
Danaher Corporation is a science and technology company organized into three segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment, established through the acquisition of Pall in 2015 and expanded by the acquisition of Cytiva in 2020, provides bioprocessing technologies, consumables, and services for the development and manufacture of biological medicines, including monoclonal antibodies, cell and gene therapies, and nucleic acid-based therapies. The Life Sciences segment, built through acquisitions such as Leica Microsystems, AB Sciex, Molecular Devices, Beckman Coulter, Phenomenex, IDT, Aldevron, and Abcam, offers instruments, consumables, and software for studying DNA, RNA, proteins, and cells to support drug discovery, development, and manufacturing. The company serves pharmaceutical and biopharmaceutical companies, contract manufacturing organizations, academic and translational research institutions, and clinical care providers. Danaher sells its products primarily through direct sales and independent distributors in North America, Europe, Asia, and high-growth markets. The company was founded in 1984 by Steven M. Rales and Mitchell P. Rales and operates under the Danaher Business System framework. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Biotechnology | Homepage danaher.com |
| Sector Healthcare | IR page investors.danaher.com | |
|
Tags
bioprocessing, cell and gene therapy, molecular diagnostics, life sciences instruments, chromatography resins, filtration technologies, liquid handling systems, centrifugation, genomic medicine, biotherapeutics, recombinant proteins, vaccines, Cytiva, Pall, Leica Microsystems, AB Sciex, Molecular Devices, Beckman Coulter, Phenomenex, IDT, Aldevron, Abcam, Radiometer, Fortive, Veralto, Blue Whale Bio
|
Press page investors.danaher.com/press-releases |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 164.001B |
| Market cap (USD) | $ 164.001B |
| P/E | 38.47 |
| PEG | — |
| P/BV | 3.06 |
| P/S | 6.40 |
| P/OCF | 23.91 |
| P/FCF | 28.64 |
| Dividend yield | <0.01% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 7.1% |
| ROI | 5.1% |
| ROIC | 5.6% |
| Profit margin | 14.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -20.6% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | 49.4% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 59 |
| Quality score | -15.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.568B | 23.875B | 23.89B | 31.471B | 29.453B | 22.284B | 17.911B | 19.893B | 18.33B | 16.882B | 20.563B | 19.914B | 19.118B | 18.26B | 16.091B | 13.203B | 11.185B | 12.697B | 11.026B | 9.596B | 7.985B | 6.889B | 5.294B | 4.577B | 3.782B | 3.778B |
| Net profit | 3.614B | 3.899B | 4.764B | 7.209B | 6.433B | 3.646B | 3.008B | 2.651B | 2.492B | 2.554B | 3.357B | 2.598B | 2.695B | 2.392B | 2.172B | 1.793B | 1.152B | 1.318B | 1.37B | 1.122B | 897.8M | 746M | 536.834M | 290.391M | 297.665M | 324.213M |
| Free cash flow | 5.26B | 5.296B | 5.781B | 7.367B | 7.064B | 5.417B | 3.316B | 3.366B | 2.858B | 2.932B | 3.169B | 3.161B | 3.034B | 2.957B | 2.292B | 1.867B | 1.612B | 1.665B | 1.484B | 1.41B | — | — | — | — | — | — |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 228.92 | 229.55 | 231.34 | 265.42 | 329.01 | 222.14 | 153.48 | 103.12 | 92.82 | 77.84 | 92.88 | 85.71 | 77.2 | 55.9 | 47.04 | 47.17 | 75.21 | 56.63 | 83.1 | 71.15 | — | — | — | — | — | — |
| Price performance 12m | -0 | -0.01 | -0.13 | -0.19 | 0.48 | 0.45 | 0.49 | 0.11 | 0.19 | -0.16 | 0.08 | 0.11 | 0.38 | 0.19 | -0 | -0.37 | 0.33 | -0.32 | 0.17 | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 3.19B | 3.52B | 3.49B | 3.19B | 4.05B | 4.63B | 4.92B | 3.92B | 3.54B | 3.91B |
| ↳ YoY growth | -19.6% | +10.5% | -0.9% | -8.5% | +26.7% | +14.5% | +6.2% | -20.3% | -9.8% | +10.6% |
| ↳ 5y CAGR | +0.9% | +1.5% | +0.2% | -2.6% | +0.4% | +7.8% | +6.9% | +2.4% | +2.1% | -0.7% |
| Borrowings, current (USD) | 2.59B | 195M | 51.8M | 212M | 11M | 8M | 591M | 1.7B | 505M | 2M |
| Borrowings, non-current (USD) | 9.67B | 10.3B | 9.69B | 21.5B | 21.2B | 22.2B | 19.1B | 16.7B | 15.5B | 18.4B |
| Lease liabilities (USD) | — | — | 1.01B | 797M | 974M | 1.1B | 1.06B | 1.13B | 1.14B | 1.28B |
| Cash and deposits (USD) | 964M | 630M | 788M | 19.9B | 6.04B | 2.59B | 6B | 5.86B | 2.08B | 4.62B |
| Intangible assets (USD) | 11.8B | 11.7B | 11.7B | 9.75B | 21.3B | 22.8B | 20.3B | 20.7B | 18.6B | 17.8B |
| Right-of-use assets (USD) | — | — | 971M | 764M | 942M | 1.04B | 1B | 1.05B | 1.08B | 1.21B |
| Net debt (borrowings + leases - cash) (USD) | 11.3B | 9.89B | 8.95B | 2.61B | 16.1B | 20.7B | 14.7B | 13.7B | 15.1B | 15.1B |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | 3.52B | 3.48B | 4.02B | 3.95B | 6.21B | 8.36B | 8.52B | 7.16B | 6.69B | 6.42B |
| Purchases of property, plant and equipment (USD) | -590M | -620M | -656M | -636M | -791M | -1.29B | -1.15B | -1.38B | -1.39B | -1.16B |
| Change in receivables (cash effect) (USD) | -183M | -161M | -58.3M | -156M | -264M | -611M | -477M | 322M | 331M | -216M |
| Change in inventories (cash effect) (USD) | 9.4M | -27.4M | -143M | -21.9M | -123M | -502M | -486M | 185M | 147M | -58M |
| Change in payables (cash effect) (USD) | 78.1M | -54.4M | 226M | 18.1M | 227M | 549M | 5M | -149M | 19M | 9M |
| Dividends paid (cash effect) (USD) | -400M | -378M | -433M | -527M | -615M | -742M | -818M | -821M | -768M | -878M |
| Share buybacks (cash effect) (USD) | — | — | — | — | — | — | 0.00 | 0.00 | -5.98B | -3.09B |
| Interest paid (cash effect) (USD) | -212M | -130M | -140M | -129M | -331M | -452M | -347M | -392M | -370M | -331M |
| Income taxes paid (cash effect) (USD) | -767M | -689M | -673M | -847M | -1.1B | -1.7B | -1.8B | -1.8B | -1.3B | -1.2B |
| Share-based compensation (USD) | 130M | 139M | 151M | 159M | 187M | 218M | 336M | 306M | 288M | 298M |
| Operating cash flow before change in receivables (USD) | 3.7B | 3.64B | 4.08B | 4.11B | 6.47B | 8.97B | 9B | 6.84B | 6.36B | 6.63B |
| Free cash flow (OCF - PPE - intangibles) (USD) | 2.93B | 2.86B | 3.37B | 3.32B | 5.42B | 7.06B | 7.37B | 5.78B | 5.3B | 5.26B |
| Income detail | ||||||||||
| Research and development expense (USD) | 975M | 1.13B | 1.23B | 1.13B | 1.35B | 1.74B | 1.75B | 1.5B | 1.58B | 1.6B |
| ↳ 5y CAGR | -0.9% | -0.2% | -0.3% | -3.0% | +1.7% | +12.3% | +9.1% | +4.1% | +7.1% | +3.5% |
| Total comprehensive income (USD) | 1.86B | 3.52B | 2.01B | 2.73B | 6.35B | 5.77B | 5.36B | 4.91B | 2.43B | 6.63B |
| Comprehensive income to owners (USD) | 1.86B | 3.52B | 2.01B | 2.73B | 6.35B | 5.77B | 5.36B | 4.91B | 2.43B | 6.63B |
| Provision for credit losses (USD) | 33M | 33M | 36M | 30M | 31M | 31M | 29M | 43M | 37M | 45M |
| Credit cost ratio (credit losses / average receivables) (%) | 0.9% | 1.0% | 1.0% | 0.9% | 0.9% | 0.7% | 0.6% | 1.0% | 1.0% | 1.2% |
| Reported | Feb 22, 2017 | Feb 21, 2018 | Apr 18, 2019 | Feb 21, 2020 | Feb 25, 2021 | Feb 23, 2022 | Feb 20, 2025 | Feb 20, 2025 | Feb 20, 2025 | Feb 24, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Danaher Reports Third Quarter 2026 Results
WASHINGTON D.C., October 21, 2026 -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
Key Third Quarter 2026 Results
•Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year.
•Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11.
•Revenues increased 8.5% year-over-year to $6.6 billion.
•Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.
•Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.
Julie Sawyer Montgomery, President and Chief Executive Officer, stated, “We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets.
WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in
this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
Key Third Quarter 2026 Results
Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year.
Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11.
Revenues increased 8.5% year-over-year to $6.6 billion.
Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.
Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.
Julie Sawyer Montgomery, President and Chief Executive Officer, stated, "We delivered better-than-expected third quarter revenue, earnings and
cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth
excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert
improving demand into strong financial performance."
Ms. Sawyer Montgomery continued, "Danaher has built a strong foundation, and the time I've spent with our teams and customers during my
transition into the CEO role has only reinforced my conviction in the opportunities ahead. Looking forward, the opportunity for Danaher is clear: to
become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth,
and helps our customers improve outcomes for patients around the world."
Fourth Quarter and Full Year 2026 Outlook
Danaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted
diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting
principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the fourth quarter and $1.9
billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to be flat in the fourth
quarter and increase sales by 1.0% in the full year, assuming the currency exchange rates in effect as of September 25, 2026) the additional
elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions,
divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to
predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional
elements could be material to our results computed in accordance with GAAP.
For the fourth quarter 2026, the Company anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0%
range year-over-year. We expect respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of
approximately 3.0%.
For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62
versus previous guidance of $8.45 to $8.60.
Conference Call and Webcast Information
Danaher will discuss its third quarter results and financial guidance for the fourth quarter and full year 2026, including as applicable key assumptions
with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be
webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the
webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the
next quarterly earnings call.
The conference call can be accessed by dialing 800-267-6316, within the U.S. or +1 203-518-9783 outside the U.S. a few minutes before 8:00 a.m.
ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ326). A replay of the conference
call will be available shortly after the conclusion of the call and until November 4, 2026. You can access the replay dial-in information on the
"Investors" section of Danaher's website under the subheading "Events & Presentations."
ABOUT DANAHER
Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to
improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many
of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the
Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and
Innovation at the Speed of Life. Explore more at www.danaher.com.
NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS
In addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures.
Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful
information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other
information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.
In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing
details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website
FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the fourth
quarter and full year 2026, the Company's expectations regarding business trends, opportunities, market share gains, sustainable profitable growth
and improved patient outcomes and any other statements regarding events or developments that we believe or anticipate will or may occur in the
future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause
actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and
you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs
and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the
acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the
financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the
impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests
and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability
to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities
and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of
Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or
growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and
expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws
and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the
results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry,
security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment
of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax
laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national
emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or
software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory
measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations
relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including
commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to
collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to
recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors
(including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in
the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum
provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is
available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2026.
These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does
not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and
developments or otherwise.
This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory
approvals, or are available only in certain markets.
DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)
Three-Month Period EndedNine-Month Period Ended
September 25, 2026September 26, 2025September 25, 2026September 26, 2025
Sales$ 6,554$ 6,053$ 18,770$ 17,730
Cost of sales(2,717)(2,530)(7,731)(7,173)
Gross profit3,8373,52311,03910,557
Operating costs:
Selling, general and administrative
expenses(2,159)(1,991)(6,091)(6,209)
Research and development
expenses(433)(378)(1,232)(1,160)
Operating profit1,2451,1543,7163,188
Nonoperating income (expense):
Other income (expense), net(9)(14)(85)(135)
Interest expense(135)(67)(305)(210)
Interest income31311917
Earnings before income taxes1,1321,0763,4452,860
Income taxes75(168)(339)(443)
Net earnings from continuing operations1,2079083,1062,417
Earnings from discontinued operations,
net of income taxes28—28—
Net earnings
$ 1,235$ 908$ 3,134$ 2,417
Net earnings per common share from
continuing operations:
Basic$ 1.71$ 1.28$ 4.40(a)$ 3.38
Diluted$ 1.71$ 1.27$ 4.38(a)$ 3.37
Net earnings per common share from
discontinued operations:
Basic$ 0.04$ —$ 0.04$ —
Diluted$ 0.04$ —$ 0.04$ —
Net earnings per common share:
Basic$ 1.75$ 1.28$ 4.44(a)$ 3.38(a)
Diluted$ 1.75$ 1.27$ 4.42(a)$ 3.37(a)
Average common stock and common
equivalent shares outstanding:
Basic703.8710.7705.7714.5
Diluted706.8713.7708.5717.9
(a)Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.
This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's
website (www.danaher.com).
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Nov 3, 2016 | Acquired | Acquired Cepheid (CIK 1037760). Its filings from before the deal are on its own company page, not shown here. |
| May 21, 2015 | Acquired | Acquired Pall Corp (CIK 75829). Its filings from before the deal are on its own company page, not shown here. |
| May 10, 2012 | Acquired | Acquired X Rite Inc (CIK 790818). Its filings from before the deal are on its own company page, not shown here. |
| May 10, 2011 | Acquired | Acquired Beckman Coulter Inc (CIK 840467). Its filings from before the deal are on its own company page, not shown here. |
| May 10, 2006 | Acquired | Acquired Sybron Dental Specialties Inc (CIK 1121302). Its filings from before the deal are on its own company page, not shown here. |
ETFs Holding Danaher Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| PRCS | 5.74% | 46,174 | $ 10.23M | Sep 30, 2026 |
| BMED | 5.19% | 3,232 | $ 743.069K | Nov 16, 2026 |
| EAGL | 5.18% | 1,158,537 | $ 220.678M | Jun 30, 2026 |
| LRGG | 4.33% | 60,038 | $ 11.436M | Jun 30, 2026 |
| CVRD | 4.29% | 7,200 | $ 1.371M | Jun 30, 2026 |
| JXX | 4.03% | 5,508 | $ 1.074M | Jul 31, 2026 |
| FMED | 3.73% | 9,000 | $ 1.922M | Aug 31, 2026 |
| NPFE | 3.57% | 118,897 | $ 23.183M | Jul 31, 2026 |
| BCHP | 3.22% | 36,941 | $ 7.037M | Jun 30, 2026 |
| EQTY | 3.22% | 235,300 | $ 45.879M | Jul 31, 2026 |
| AIVL | 3.07% | 67,025 | $ 12.767M | Jun 30, 2026 |
| HRTS | 2.98% | 7,756 | $ 1.656M | Aug 31, 2026 |
| TMED | 2.96% | 3,580 | $ 681.918K | Jun 30, 2026 |
| JDOC | 2.79% | 1,223 | $ 276.117K | Nov 17, 2026 |
| ASLV | 2.62% | 29,365 | $ 5.726M | Jul 31, 2026 |
| BASG | 2.56% | 66,390 | $ 12.646M | Jun 30, 2026 |
| GRW | 1.92% | 6,380 | $ 1.244M | Jul 31, 2026 |
| THMZ | 1.88% | 5,346 | $ 1.018M | Jun 30, 2026 |
| CGVV | 1.74% | 15,400 | $ 3.541M | Nov 16, 2026 |
| BAFE | 1.72% | 152,974 | $ 29.138M | Jun 30, 2026 |
| TCAL | 1.45% | 20,890 | $ 4.803M | Nov 17, 2026 |
| TCAF | 1.43% | 667,895 | $ 153.556M | Nov 17, 2026 |
| ROPE | 1.34% | 1,464 | $ 330K | Nov 18, 2026 |
| MEDI | 1.30% | 2,524 | $ 585.972K | Nov 12, 2026 |
| PSET | 1.24% | 1,868 | $ 355.817K | Jun 30, 2026 |
| AGRW | 1.10% | 6,377 | $ 1.243M | Jul 31, 2026 |
| TGLB | 1.07% | 1,437 | $ 280.186K | Jul 31, 2026 |
| BKDV | 1.03% | 96,880 | $ 18.89M | Jul 31, 2026 |
| CGCV | 1.02% | 108,904 | $ 25.038M | Nov 16, 2026 |
| FPAG | 0.99% | 28,133 | $ 5.359M | Jun 30, 2026 |
| SURE | 0.99% | 2,527 | $ 570.521K | Nov 17, 2026 |
| CGGE | 0.96% | 136,133 | $ 31.298M | Nov 16, 2026 |
| SPIN | 0.96% | 1,854 | $ 426.253K | Nov 16, 2026 |
| JAVA | 0.93% | 307,255 | $ 69.369M | Nov 17, 2026 |
| ACLC | 0.85% | 12,931 | $ 2.762M | Aug 31, 2026 |
| MKTN short | -0.79% | -4,410 | $ -840.017K | Jun 30, 2026 |
| LVDS | 0.78% | 4,150 | $ 936.946K | Nov 17, 2026 |
| PRAY | 0.77% | 3,169 | $ 603.631K | Jun 30, 2026 |
| MFSG | 0.68% | 12,090 | $ 2.582M | Aug 31, 2026 |
| JSTC | 0.66% | 8,453 | $ 1.943M | Nov 17, 2026 |
| PINK | 0.61% | 9,089 | $ 2.052M | Nov 17, 2026 |
| FFLC | 0.59% | 36,489 | $ 7.115M | Jul 31, 2026 |
| HELX | 0.57% | 842 | $ 160.384K | Jun 30, 2026 |
| PAPI | 0.56% | 11,779 | $ 2.244M | Jun 30, 2026 |
| ACVU | 0.55% | 6,771 | $ 0.00 | Nov 18, 2026 |
| CAPE | 0.55% | 6,871 | $ 1.309M | Jun 30, 2026 |
| TIME | 0.54% | 350 | $ 80.469K | Nov 17, 2026 |
| FELV | 0.49% | 81,816 | $ 15.584M | Jun 30, 2026 |
| BDYN | 0.43% | 56,218 | $ 12.925M | Nov 16, 2026 |
| DFUV | 0.41% | 278,400 | $ 64.633M | Nov 12, 2026 |
| MODL | 0.36% | 19,417 | $ 3.699M | Jun 30, 2026 |
| XMAG | 0.34% | 3,165 | $ 734.786K | Nov 13, 2026 |
| NBCR | 0.34% | 13,404 | $ 2.863M | Aug 31, 2026 |
| FELC | 0.32% | 131,039 | $ 24.96M | Jun 30, 2026 |
| GPT | 0.31% | 390 | $ 74.287K | Jun 30, 2026 |
| WINN | 0.30% | 16,787 | $ 3.912M | Nov 13, 2026 |
| INRO | 0.29% | 7,502 | $ 1.725M | Nov 16, 2026 |
| LDRX | 0.28% | 3,379 | $ 721.619K | Aug 31, 2026 |
| DFLV | 0.28% | 92,391 | $ 21.449M | Nov 12, 2026 |
| TVAL | 0.24% | 12,072 | $ 2.775M | Nov 17, 2026 |
| GSPY | 0.24% | 7,203 | $ 1.656M | Nov 17, 2026 |
| ACVF | 0.23% | 1,783 | $ 347.649K | Jul 31, 2026 |
| STOX | 0.23% | 2,383 | $ 508.913K | Aug 31, 2026 |
| DFUS | 0.21% | 197,815 | $ 45.925M | Nov 12, 2026 |
| SFTY | 0.21% | 7,839 | $ 1.674M | Aug 31, 2026 |
| GDE | 0.20% | 4,449 | $ 950.128K | Aug 31, 2026 |
| NTSD | 0.20% | 368 | $ 70.097K | Jun 30, 2026 |
| TACU | 0.19% | 155 | $ 35.636K | Nov 17, 2026 |
| VOXP | 0.19% | 57 | $ 11.114K | Jul 31, 2026 |
| CGNG | 0.19% | 23,689 | $ 5.446M | Nov 16, 2026 |
| ADME | 0.19% | 2,836 | $ 552.963K | Jul 31, 2026 |
| ACIO | 0.19% | 22,752 | $ 4.436M | Jul 31, 2026 |
| GEW | 0.18% | 1,245 | $ 265.882K | Aug 31, 2026 |
| APUE | 0.18% | 20,690 | $ 4.419M | Aug 31, 2026 |
| AAUS | 0.17% | 3,905 | $ 880K | Nov 18, 2026 |
| DFSU | 0.16% | 16,876 | $ 3.918M | Nov 12, 2026 |
| DFAU | 0.16% | 90,680 | $ 21.052M | Nov 12, 2026 |
| NTSX | 0.16% | 11,606 | $ 2.211M | Jun 30, 2026 |
| LGDX | 0.16% | 967 | $ 222.323K | Nov 17, 2026 |
| HCMT | 0.15% | 4,381 | $ 854.207K | Jul 31, 2026 |
| MSLC | 0.15% | 28,552 | $ 6.098M | Aug 31, 2026 |
| VFVA | 0.14% | 6,376 | $ 1.362M | Aug 31, 2026 |
| DCOR | 0.14% | 271,219 | $ 62.966M | Nov 12, 2026 |
| THRO | 0.11% | 51,163 | $ 11.763M | Nov 16, 2026 |
| DFAC | 0.11% | 411,150 | $ 95.453M | Nov 12, 2026 |
| AVUS | 0.10% | 60,633 | $ 13.94M | Nov 16, 2026 |
| AVSU | 0.10% | 2,104 | $ 483.731K | Nov 16, 2026 |
| DYNF | 0.10% | 171,895 | $ 39.52M | Nov 16, 2026 |
| AVLC | 0.09% | 6,432 | $ 1.479M | Nov 16, 2026 |
| CSHP | 0.08% | 1,283 | $ 294.975K | Nov 16, 2026 |
| FBCG | 0.07% | 25,158 | $ 4.905M | Jul 31, 2026 |
| DAK | 0.07% | 125 | $ 30K | Nov 18, 2026 |
| DXUV | 0.05% | 13,644 | $ 3.168M | Nov 12, 2026 |
| IALT short | -0.05% | -15,806 | $ -3.634M | Nov 16, 2026 |
| EBI | 0.02% | 627 | $ 133.902K | Aug 31, 2026 |
| CORO | 0.00% | 395 | $ 90.721K | Nov 16, 2026 |
| JUSA | 0.00% | 2 | $ 451.54 | Nov 17, 2026 |



